anemia hemophilia

Patients will be monitored through 28 weeks with an
additional visit at week 54 for a final blood test., D.

duncans thalassemia

David Perlmutter and Bruce Trapnell. ( http://www.

leukemia hemophilia

Scientific Meeting on Alpha -1 Antitrypsin Deficiency and Other Liver Diseases Caused by Aggregated Proteins

211

autologous apheresis

Sc.

blood myeloma

Centocor is a wholly owned subsidiary of Johnson & Johnson, the worldwide
manufacturer of healthcare products.

willebrand lymphedema

PRESS RELEASE Centocor Extends Patient Enrollment to Evaluate CNTO 1275 in Treatment of Active Crohn's Disease

CNTO 1275 is a
human monoclonal antibody that targets interleukin 12 (IL-12 ) and
interleukin 23 (IL-23), proteins that occur naturally in the immune system
and are believed to play a role in the inflammation associated with CD.
The objectives of the conference are to understand the molecular biology
of protein folding, the role of the protein degradation system, and the
consequences of misfolding of specific proteins seen in several clinical
disorders. This conference will highlight studies and future research
opportunities which may help to define molecular approaches underway to
develop effective therapies to treat the liver manifestations of disorders
involving protein misfolding. "This Workshop will build upon the work of
the Foundation's previous scientific conferences and the significant recent
advances in the understanding of AAT Deficiency ." For a full agenda and
information, visit: http://www.

platelet lymphedema

"This study will evaluate the effect of a targeted, human anti-IL-12
monoclonal antibody on Crohn's disease and its symptoms," said Dennis S. "We look forward to further analysis and evaluation of this
therapy as a potential treatment for patients with moderate to severe
Crohn's disease.org .

lymphoproliferative duncans

For more information about clinical trial sites and specific study
protocol, please call 1-800-624-7994. Experts From Around the World to Convene in Atlanta

MIAMI, The Alpha-1 Foundation, in conjunction with
the American Association for the Study of Liver Diseases (AASLD) has organized
a Basic Research Single Topic Conference on Alpha-1 Antitrypsin Deficiency and
Other Liver Diseases Caused by Aggregated Proteins on January 26-28, in
Atlanta, GA.

The AASLD is a leading organization of scientists and healthcare
professionals committed to preventing and curing liver disease.

lymphedema nhlbi

Other sponsors include the National Institutes of Health --
National Institute of Diabetes and Digestive and Kidney Diseases , and Office
of Rare Diseases -- and American Liver Foundation.org )

Contact: Marlene Erven
+1-305-567-9888, ext.

duncans leukemia

"We are pleased that Aaron Ciechanover, M.

lymphoproliferative drgreene

M.

apheresis willebrand

"

Patients who are eligible to participate in the 28-week study will be
randomized at week 0 to one of four treatment groups to receive active drug
or placebo.

lymphedema willebrand

apheresis coagulation

transfusion coagulation

Subjects will be permitted to remain on certain standard CD
medications, including steroids and immunomodulators, while participating
in the study .D.

xlp myeloma

About Centocor

Centocor is a leading biopharmaceutical company that creates, acquires and
markets cost-effective therapies that yield long-term benefits for patients
and the healthcare community. Participants will discuss the current concepts of the molecular
mechanisms responsible for liver injury in patients with Alpha-1 Antitrypsin
Deficiency.

The Alpha-1 Foundation is dedicated to providing the leadership and
resources that will result in increased research, improved health, worldwide
detection and a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1).

apheresis duncans

announced today the
extension of patient enrollment for a Phase II trial to evaluate the safety
and efficacy of CNTO 1275 for reducing the signs and symptoms of active
Crohn's disease (CD), a serious gastrointestinal disorder.), such as arthritis and
inflammatory skin diseases. Centocor's products, developed primarily
through monoclonal antibody technology, help physicians deliver innovative
treatments to improve human health and restore patients' quality of life.

Balistreri, M.

lymphoma neutropenia

The disease causes inflammation of the
gastrointestinal tract, typically resulting in symptoms such as diarrhea,
fever, abdominal pain and weight loss.D., Director, Pediatric Liver Care Center, Cincinnati Children's
Hospital Medical Center.aasld.org )

The American Liver Foundation is the nation's leading nonprofit
organization promoting liver health and disease prevention.

xlp neutropenia

About Crohn's Disease

CD is a chronic inflammatory bowel disorder that commonly affects the lower
part of the small intestine and the large intestine and typically begins in
late childhood or early adulthood. The company is dedicated to the research and
development of treatments for a wide range of diseases including cancer,
infectious diseases , cardiovascular and metabolic diseases and
Immune-Mediated Inflammatory Disorders (I. Dr Balistreri is conference co-director with
Drs.alphaone.liverfoundation.

duncans leukemia

"This is a novel gathering of scientists and clinicians in related areas
to focus on the important emerging topic of the molecular pathogenesis and
therapeutic approaches to the hepatotoxicity associated with the inherited
metabolic disorder Alpha-1 Antitrypsin Deficiency," says William F.

anemia myeloma

I.

lymphoproliferative willebrand

sickle thalassemia

Centocor, Inc. It is estimated that 500,000
Americans and more than 400,000 people in Europe and Canada suffer from
this gastrointestinal disorder.D., the 2004 Nobel Prize
Winner in Chemistry, will be a featured presenter," says John Walsh , President
and CEO of the Alpha-1 Foundation. Alpha-1 is
a genetic disorder that can cause liver and lung disease in children and
adults.
( http://www.

leukemia lymphoma

Riff, MD, Medical Director, Advanced Clinical Research Institute, Anaheim,
California.

lymphedema xlp

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)